Massachusetts Senator Elizabeth Warren, along with seven other Senators, has directed a letter to the Obama administration demanding regulators answer questions specific to the facilitation of research into the medical benefits of marijuana.
Senators acknowledged the need for unbiased research. They wrote, “While the federal government has emphasized research on the potential harms associated with the use of marijuana, there is still very limited research on the potential health benefits of marijuana — despite the fact that millions of Americans are now eligible
by state law to use the drug for medical purposes.”
The Senators applauded a recent decision by the Department of Health and Human Services to eliminate the HHS Public Health Service review process. But they also acknowledged the drawbacks of NIDA’s monopoly on supply of marijuana for research purposes and the need for alternative providers.
Senators also questioned marijuana’s current classification as a Schedule 1 drug under federal law and its classification under international treaties and if the FDA is prepared to call for the reclassification of cannabidiol.
Addressed to the heads of the Department of Health and Human Services (HHS), the Drug Enforcement Administration (DEA), and the Office of National Drug Control Policy, the letter signals to many that medical marijuana is becoming an even more important issue in the political sphere not only to voters but also to their elected officials.
Co-signing the letter with Senator Warren were Senators Barbara Mikulski (D-Md.), Barbara Boxer (D-Calif.), Ron Wyden (D-Ore.), Jeff Merkley (D-Ore.), Kirsten Gillibrand (D-N.Y.), Edward J. Markey (D-Mass.), and Cory Booker (D-N.J.). The Senators are seeking a reply to their questions from the administration by August 31.
For over 45 years NORML has been at the center of national efforts to legalize responsible use of marijuana by adults. But missing from these efforts was an accurate way to measure impairment. Today we’re happy to announce such a way exists and it’s called Canary.
“Canary is the first app to give consumers the scientific information they need to honestly and accurately evaluate their personal performance, privately, anytime, and anywhere,” says Allen St. Pierre, Executive Director of NORML.
Available for iPhone® and iPad®, Canary combines decades of research and experience, specialized mental and physical performance tests, and sophisticated analysis to accurately measure impairment due to alcohol, medication, fatigue and even the subtle impact of marijuana.
Download and Canary yourself: https://appsto.re/us/QYxB7.i
As a special offer for NORML members, the first 500 downloads of Canary are free. Afterwards the app will be available for $4.99 and a percentage of each sale will go to support responsible consumption initiatives at NORML.
Please try Canary and send us your feedback.
The NORML Team
P.S. For more information about responsible marijuana use visit:
FOR IMMEDIATE RELEASE
Contact: Allen St. Pierre: firstname.lastname@example.org, (202) 483-5500
Organization: National Organization for the Reform of Marijuana Laws (NORML)
Web Site: www.norml.org
iTunes App Store: https://appsto.re/us/QYxB7.i
Additional Contact: Marc Silverman: email@example.com
Canary App Permits Marijuana Consumers To Gauge Their Personal Performance
WASHINGTON, D.C., July 15, 2015. Representatives of the National Organization for the Reform of Marijuana Laws (NORML) today endorsed Canary, the first-ever mobile app that quickly and accurately measures one’s personal performance to determine whether or not a subject may be under the influence of marijuana. Available for iPhone® and iPad®, Canary combines decades of research and experience, specialized mental and physical performance tests, and advanced modeling and analysis to accurately measure behavioral or cognitive impairment. Interested parties may view a full demonstration of the Canary app:
“NORML’s purpose is to influence public opinion to legalize the responsible use of marijuana,” said Allen St. Pierre, Executive Director of NORML. “Canary is the first app to provide consumers with the scientific information they need to accurately evaluate their personal performance, privately, anytime, and anywhere.”
Canary features four distinct mental and physical performance tests, designed to evaluate baseline performance, and then to compare subjects’ behavior against this established baseline. Potential deviation in baseline performance as a result of the use of cannabis, alcohol, prescription drugs, or even exhaustion, is readily identified by the app.
To form this overall picture, Canary uses state-of-the-art metrics and advanced features of the iPhone 4s and later, to measure and record:
- Reaction Time and Divided Attention
- Time Perception
The Canary tests can be completed in two minutes and the results are immediately analyzed to determine the individual user’s performance level. Average performance data from a large group of unintoxicated individuals is used to assess impairment. For greater accuracy, users can set a unique personal baseline; then future tests are measured against this personal baseline.
“Canary is the culmination of 60 years of combined technical and legal experience and thousands of peer-reviewed studies, including NASA, NHTSA, and DOD research, as well as upon thousands of studies specific to cannabis’ acute impact on cognitive and psychomotor functioning,” said Marc Silverman, Canary’s developer. “Canary measures key performance indicators that may be impacted by potentially impairing substances, including marijuana, while respecting users’ privacy. Canary doesn’t share users personal data with anyone.”
“The identification of THC in blood is poorly associated with users’ impairment of performance,” said Leonard Frieling, a published author on the impact of marijuana on functioning and an a ttorney of 39 years. He is also a member of the NORML Legal Committee , Colorado NORML, and (while speaking for himself only) the first Chair of the Colorado Bar Association Marijuana Law Committee. “Canary is the first app to use performance science to help marijuana users consume more responsibly, ” he said. He added: “Of great importance is that Canary is not limited to marijuana’s impact, alcohol’s impact, or any specific cause of behavioral impairment. What we all need to know, on the spot, is ‘are we functioning up to our personal ‘normal’ standards?'”
According to a recent Gallup poll, nearly half of Americans are concerned about how the implementation of statewide marijuana legalization laws may impact traffic safety.
Such concerns pose a potential impediment to the enactment of additional marijuana law reforms. The Canary app seeks to respond to these concerns in a way that utilizes the best available science to assure personal responsibility and safety.
For more information visit: www.mycanaryapp.com
Canary is compatible with iOS 7.1 and iPhone versions 4S and newer.
For more information regarding cannabis and psychomotor performance, please see: http://norml.org/library/driving-and-marijuana.
NORML’s mission is to move public opinion sufficiently to legalize the responsible use of marijuana by responsible adults. NORML’s Principle of Responsible Use state, “The responsible cannabis consumer does not operate a motor vehicle or other dangerous machinery while impaired by cannabis.” To read NORML’s full Principles, visit: http://norml.org/principles/item/principles-of-responsible-cannabis-use-3.
States that permit qualified patients to access medical marijuana via dispensaries possess lower rates of opioid addiction and overdose deaths, according to a study published by the National Bureau of Economic Research, a non-partisan think-tank.
Researchers from the RAND Corporation and the University of California, Irvine assessed the impact of medical marijuana laws on problematic opioid use, as measured by treatment admissions for opioid pain reliever addiction (compiled from the years 1992 to 2012) and by state-level opioid overdose deaths (compiled from the years 1999 to 2013).
“[S]tates permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not,” authors reported. They found that women over the age of 40 showed the most significant decrease in problematic opioid use.
Data published last year in the Journal of the American Medical Association (JAMA) Internal Medicine reported that the enactment of statewide medicinal marijuana laws is associated with significantly lower state-level opioid overdose mortality rates. “States with medical cannabis laws had a 24.8 percent lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws,” investigators reported.
Overdose deaths involving opioid analgesics have increased dramatically over the past decade. While fewer than 4,100 opiate-induced fatalities were reported for the year 1999, by 2010 this figure rose to over 16,600 according to an analysis by the US Centers for Disease Control.
An abstract of the study, “Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers?”, is available online here.
The use of marijuana by younger adolescents is falling while their perceived disapproval of cannabis use is rising, according to data published this week in The American Journal of Drug and Alcohol Abuse.
Investigators from the University of Texas at Austin evaluated trends in young people’s attitudes toward cannabis and their use of the substance during the years 2002 to 2013 – a time period where 14 states enacted laws legalizing the medical use of the plant, and two states approved its recreational use by adults. (Six states also enacted laws decriminalizing marijuana possession offenses during this time.) Analyses were based on self-reported measurements from a nationally representative sample of 105,903 younger adolescents (aged 12-14); 110,949 older adolescents (aged 15-17); and 221,976 young adults (aged 18-25).
Researchers reported that the proportion of adolescents age 12 to 14 who strongly disapproved of marijuana use rose significantly during this period. The percentage of 12 to 14-year-olds reporting having used marijuana during the past year fell significantly during this same time period.
Among youth age 15 to 17, past year cannabis use also fell significantly, while young people’s perception of marijuana remained largely unchanged.
“Our results may suggest that recent changes in public policy, including the decriminalization, medicalization, and legalization of marijuana in cities and states across the country, have not resulted in more use or greater approval of marijuana use among younger adolescents,” the study’s lead investigator said in a press release.
Young adults age 18 to 25, in contrast to their younger peers, were less likely in 2013 to disapprove of the use of cannabis. However, this change in attitude was not positively associated with significant rises in past year marijuana use by members of this age group, researchers reported.
Separate survey data reported by the University of Michigan has reported an overall decline over the past decade in the percentage of young people perceiving a “great risk” associated with the use of marijuana. However, this decline in perceived risk has not been accompanied by a parallel increase in cannabis use by young people.
The abstract of the study, “Trends in the disapproval and use of marijuana among adolescents and young adults in the United States: 2002-2013,” appears online here.
Democrat Gov. Jerry Brown signed legislation today, Assembly Bill 258, to allow medical marijuana patients to receive organ transplants.
Hospitals in California and elsewhere have denied patients from receiving organ transplants solely based on their status as medicinal marijuana consumers. Assembly Bill 258 reads, “A hospital, physician and surgeon, procurement organization, or other person shall not determine the ultimate recipient of an anatomical gift based solely upon a potential recipient’s status as a qualified patient, as defined in Section 711362.7, or based solely upon a positive test for the use of medical marijuana by a potential recipient who is a qualified patient.”
Passage of AB 258 ends these discriminatory practices in California.
The new law takes effect on January 1, 2016.
According to a study published in the American Journal of Transplantation, marijuana use by patients undergoing transplants does not adversely impact survival rates.